Osterweis Capital Management Inc. Takes Position in Amicus Therapeutics, Inc. $FOLD

Key Points

• Osterweis Capital Management Inc. has acquired a new stake in Amicus Therapeutics, Inc., purchasing approximately 824,740 shares valued at around $6.73 million during the first quarter.
• Amicus Therapeutics received mixed ratings from analysts, with Morgan Stanley upgrading its rating to "overweight," while Wall Street Zen downgraded it to "hold," resulting in a consensus rating of "Moderate Buy."
• The stock currently trades at $8.02, with a market capitalization of $2.47 billion and a 52-week range between $5.51 and $12.65.

Osterweis Capital Management Inc. acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 824,740 shares of the biopharmaceutical company's stock, valued at approximately $6,730,000. Osterweis Capital Management Inc. owned 0.27% of Amicus Therapeutics as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of FOLD. Ameriprise Financial Inc. lifted its holdings in shares of Amicus Therapeutics by 4.2% in the fourth quarter. Ameriprise Financial Inc. now owns 403,127 shares of the biopharmaceutical company's stock valued at $3,797,000 after buying an additional 16,179 shares during the period. Cetera Investment Advisers acquired a new stake in shares of Amicus Therapeutics in the fourth quarter valued at $113,000. Deutsche Bank AG lifted its holdings in shares of Amicus Therapeutics by 11.9% in the fourth quarter. Deutsche Bank AG now owns 822,108 shares of the biopharmaceutical company's stock valued at $7,744,000 after buying an additional 87,491 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Amicus Therapeutics by 10.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 258,149 shares of the biopharmaceutical company's stock valued at $2,432,000 after buying an additional 24,316 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Amicus Therapeutics by 10.8% in the fourth quarter. Millennium Management LLC now owns 457,014 shares of the biopharmaceutical company's stock valued at $4,305,000 after buying an additional 44,449 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $8.02 on Friday. The firm's 50 day simple moving average is $6.91 and its 200-day simple moving average is $7.02. The company has a market cap of $2.47 billion, a P/E ratio of -66.83 and a beta of 0.55. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.